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ABSTRACT 
Background: Diabetes is one of the largest health emergencies of the twenty-first century 
globally. The development of long-term complications is influenced by hyperglycemia and 
poor glycemic control of diabetes mellitus could accelerate their progression. For provision of 
standard care for the patients, objective information regarding the magnitude of poor glycemic 
control is needed 
Objective: To assess glycemic control and its associated factors among glucometer user and 
non-user diabetes mellitus patients at Ayder comprehensive specialized hospital, Mekelle, 
Northern Ethiopia. 
Methods: Institution based comparative cross-sectional study was conducted from March 1 to 
April 30, 2017. The participants were enrolled in the study by using quota sampling technique. 
A structured questionnaire was used to collect socio demographic data and other relevant 
clinical characteristics. Glycated Haemoglobin A1c, Serum fasting blood sugar and lipid 
profile were determined using HumaMeter A1c (HUMAN, Germany) and ABX PENTRA 400 
clinical chemistry analyzer (HORIB ABX Diagnostics, France). Data was analyzed using 
Statistical Package for Social Sciences version 20. Independent t-test, binary and multiple 
logistic regression analysis were used. P-value <0.05 and corresponding 95% confidence 
interval were considered for statistically significance. 
Result: A total of 336 Diabetes mellitus participants participated in this study, of these, 168 
(50%) were glucometer users and the rest were non-users. Overall 208(61.9%) of the study 
participants had poor glycemic control. The poor glycemic control was significantly higher in 
non-glucometer user 120(71.4%) compared to glucometer user 88(52.4%) (P-value <0.001). 
The mean HbA1C was significantly higher among non-users than glucometer users (8.4 ±2.24 
vs. 7.68 ±1.95) (p-value<0.001). It was found that age, income, the number of visits, the level 
of high triglyceride, the level of high low-density lipoprotein and non-glucometer use were 
significantly associated with the poor glycemic control.  
Conclusion: Glucometer use is associated with lower HbA1c and decreased odds of having 
poor glycaemic control compared to non-glucometer user. Therefore, SMBG recommended to 
facilitating better glycemic control. 
Key words: Diabetes Mellitus, Glucometer, Glycemic control, Self-monitoring blood glucose
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1. INTRODUCTION 
1.1 Background 
Diabetes mellitus (DM) is a metabolic disorder of multiple etiologies characterized by chronic 
hyperglycemia with disturbances of carbohydrate, fat and protein metabolism, resulting from 
defects in insulin secretion, insulin action, or both (1). The majority of cases of DM fall into 
two broad categories: type 1 and 2 DM. Type 2 DM, which accounts for ∼90–95% of those 
with DM, encompasses individuals who have insulin resistance and usually have relative 
(rather than absolute) insulin deficiency (1, 2). Type 1 DM is characterized by an absolute 
deficiency of insulin secretion caused by pancreatic β- cell destruction, usually resulting from 
an autoimmune attack. It accounts for approximately 10% of all cases (3). 
The prevalence of both type 1 and type 2 DM is increasing worldwide. Type 2 DM is rising 
much more rapidly, presumably because of increasing obesity, reduced physical activity levels 
as countries become more industrialized, and the aging of the population (4). According to 
International Diabetes Federation( IDF) DM Atlas 2015 report, more than 75% of people with 
DM live in low and middle income countries (5). In Africa region DM is expected to be the 
highest in the future time. It also reported 3.8% regional prevalence of DM and will rise to 
4.3% in 2030. Cases of DM in Ethiopia has estimated  about 1.4 million and prevalence of 
3.32%  (6). 
To lower blood glucose levels for DM patients, management of diet, injection of insulin, and 
oral medication are currently available. Patient education and self-care practices are also 
important aspects of disease management that help patients with DM to lead normal lives (7). 
American Diabetes Association (ADA) recommends routine self-monitoring blood glucose 
(SMBG) for DM patients (8).  It is an important component of modern therapy for DM. Self-
monitoring of glycemic control is a cornerstone of DM care that can ensure patient 
participation in achieving and maintaining specific glycemic targets. The most important 
objective of monitoring is the assessment of overall glycemic control and initiation of 
appropriate steps in a timely manner to achieve optimum control (9).   
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Glycated hemoglobin (HbA1c) is one of the Glycated hemoglobins, a subfraction formed by 
the attachment of various sugars to the Hb molecule. HbA1c is formed in two steps by the non-
enzymatic reaction of glucose with the N-terminal amino group of the β-chain of normal adult 
Hb (HbA). The first step is reversible and yields labile HbA1c. This slowly rearranges in the 
second reaction step to yield stable HbA1c. In the erythrocytes, the relative amount of HbA 
converted to stable HbA1c increases with the average concentration of glucose in the blood. 
The conversion to stable HbA1c is limited by the erythrocyte’s life span of approximately 100 
to 120 days. As a result, HbA1c reflects the average blood glucose level during the preceding 
2 to 3 months. It is thus suitable to monitor long-term blood glucose control in individuals with 
DM. More recent glucose levels have a greater influence on the HbA1c level (10). The ADA 
recommendation of optimal glycemic control in DM patients is HbA1c level of <7% (2). 
 
Different researchers had shown that poor glycemic control of DM patients leads to 
microvascular and macrovascular complications (11-13). However, lowering HbA1 
concentrations (by tight glycemic control) significantly reduces the rate of progression of 
microvascular complications. For instance, dropping HbA1 from 9.1–7.3 % reduces the risk of 
macrovascular disease by 41 %, retinopathy by 63%, neuropathy by 60 %, and nephropathy 
by 54 %. Every increase in HbA1 can increase the cardiovascular event rate by up to 18 % and 
the microvascular event rate by up to 30 % (11-13). 
 
The use of SMBG was associated with decrease in HbA1c levels only when the results of 
SMBG were utilized to modify therapeutic regimens (14). In clinical practice, many barriers 
can be responsible for a reduced effect of SMBG in patients not taking insulin. In fact, the 
patient is supposed to learn accurate and reliable monitoring skills, proper interpretation of the 
results, and how to use the results to adjust medical nutrition therapy, exercise, and 
pharmacologic therapy to achieve specific glycemic goals (15). Unfortunately, many patients 
either are not taught the self-management skills required lowering the measured glucose 
values, or they are not able to act on self-monitoring results. As a consequence, self-monitoring 
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can be associated with discomfort, poor acceptance of the disease and increased worries about 
the consequences of diabetes (16). 
 
The underutilization of the information deriving from self-monitoring also precludes the 
possibility of targeting and monitoring postprandial hyperglycaemia, an essential determinant 
of metabolic control and diabetes complications (17). From an economical perspective, the 
costs of blood glucose monitoring are considerable (18). In order not to waste resources, it is 
important that people with diabetes are able to utilize home monitoring effectively through 
diabetes education. Without this education to know when and how to test, and what to do with 
the results, home monitoring can fail to produce the expected benefits. 
A major advantage of Point of Care Testing (POCT) is, it can be used in any setting,  easy to 
operate, use of minimal blood volumes and provides immediate results (19). Furthermore, data 
downloaded from glucometers can be used in conjunction with written records in log books to 
evaluate glucose patterns and formulate more precise and efficacious therapeutic regimens 
(20). Therefore the aim of this study is to assess glycemic control and its associated factors 
among glucometer user and non-user DM patients as a POCT.  
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1.2 STATEMENT OF THE PROBLEM 
Diabetes is undoubtedly one of the largest health emergencies of the twenty-first century.  A 
worldwide prevalence of 8.5% in 2015 (21), which is predicted to reach 642 million by 2040. 
The largest increase will take place in regions where economies are moving from low to middle 
income levels. About 75% of people with DM live in low and middle income countries (5). 
The magnitude of poor glycemic control in DM patients in different parts of the world is high. 
For instance, a study conducted in Malaysia showed 75.3 %, in Spain 45 %, in Jordan 65.1 % 
and in Ethiopia 94 % (22-25). Different studies indicated that there are many contributing 
factors to poor glycemic control. These include older age, female sex, ethnic variation, drinking 
alcohol, higher BMI, smoking, longer duration of DM, lower physical activity, lack of 
adherence to diabetes management (such as diabetes self-care management), and many others 
(22, 26).  
Access to standard DM management in sub-Saharan Africa (SSA) was extremely limited 
because of insufficient healthcare systems; scarcity of professionals with satisfactory training 
in DM diagnosis and treatment; scarcity or unaffordability of medication, glucometer strips 
and scarcity of diagnostic tools and other equipment (27, 28). Moreover, health care in SSA is 
epidemiologically known with a high burden of communicable diseases and scarcity of 
financial and human resources. DM presents an additional challenge by accounting for the 75% 
of deaths in people due to DM  under the age of 60 annually (6, 29). 
The cost of treatment and death of DM arise mainly from its complications, such as heart 
diseases, stroke, amputations, kidney failure and serious infections. These can be prevented or 
long-delayed by inexpensive, patient self-care practice by monitoring their blood sugar, blood 
pressure level, quit smoking and alcohol and practice that reduces bad cholesterol and by 
adopting a healthy diet and exercise (29, 30). 
Poor glycemic control is the most common cause of hospital admissions and complications in 
DM (5, 31). Evidence shows that maintaining good glycemic control is a main therapeutic goal 
for all patients with DM to prevent organ damage and other micro-vascular and macro-vascular 
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complications. Glycemic control, however, is not an easy task for many patients. It is well 
known that even in clinical trials, and routinely in clinical practice, the majority of patients fail 
to achieve good glycemic control (31). 
Different studies showed that good glycemic control is achieved in less than 50% of DM 
patients (22-25). The reasons for this failure are complex and multi factorial of which both 
patient and healthcare provider related factors may contribute to poor glycemic control (32). 
However, proving exactly what factors lead to the loss of glycemic control can be challenging. 
Studies with DM patients have found correlations between poor glycemic control and factors 
such as socio demographic characteristics, insulin therapy, knowledge and skill deficit, poor 
adherence to insulin regimen, self-care, exercise and dietary plan combined with the poor 
interaction between the patient and health care providers (33). Significant knowledge and skill 
deficits have been found among 50–80% of DM patients who failed to achieve good glycemic 
control (34).  
For provision of standard care for the patients, objective information regarding the magnitude 
of poor glycemic control is needed; however, studies on the assessment of glycemic control 
using HbA1c in Ethiopia are very scarce. Limited research done on glycemic control and its 
associated factors among glucometer user and non-user DM patients in the study area. 
Therefore, the finding of this study will fill the information gap about glycemic control and its 
associated factors among glucometer user and non-user DM patients as a POCT. 
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1.3  LITERATURE REVIEW 
1.3.1 Proportion of Glycemic Control 
One of the primary goals of DM management is to lower blood glucose levels because it is 
well established that improved glycemic control delays the onset and retards the progression 
of microvascular and macrovascular complications (35). As such, regular testing of blood 
glucose is a cornerstone and achievement of adequate glycemic control is a goal for proper 
DM care (36).  
 
A cross-sectional study conducted in India to assess factors associated with a poor glycemic 
control in Type 2 DM patients. Poor glycemic was observed in 78.6% (37). Different figures 
were reported for poor  glycemic control by similar studies conducted in Jordan 65.1% (38), 
Saudi Arabia 78% (39), Cameroon and Guinea 74% (40) and Tanzania 69.7% (41). 
 
A longitudinal study conducted on the role of self-monitoring of blood glucose and intensive 
education in patients with Type 2 DM not receiving insulin in Italy. The study showed that the 
proportion of poor glycemic control was 38.1% among participants performed SMBG and 80% 
among participants non performed SMBG (had  HbA1c ≥ 7%) (42). 
 
A Cross-sectional study conducted on the relationship between self-monitoring of blood 
glucose and glycemic control among patients attending a specialist DM clinic in Jamaica. The 
finding showed that 52.5% Patients performing SMBG and 61.9% Patients not performing 
SMBG had HbA1c ≥ 7% (43).  
A cross-sectional study conducted on factors associated with poor glycemic control among 
patients with Type 2 DM in Jordan. The study estimated the proportion of patients with Type 
2 DM who did not achieve a target level of HbA1c.  Poor glycemic control (HbA1c ≥7%) was 
present in 65.1% of patients. The proportion of poor glycemic control among  participants 
performing SMBG and participants not  performing SMBG were 51.1% and 73.8 respectively 
(26).)  
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A cross-sectional study conducted in Gonder Referal Hosptal, Ethiopia, to assess Level of 
sustained glycemic control and associated factors among patients with DM. Poor glycemic 
control was observed in 64.7% of the patients had HbA1c ≥7%) (44). A similar study 
conducted in Jima, Ethiopia reported 58.2% (45) and a study conducted  among patients with 
type 2 DMin Ambo Hospital, Ethiopia, which showed 50% of the participants were  poor 
glycemic control (46).  
1.3.2 Factors Associated with Glycemic Control 
A retrospective cohort study conducted in Germany has shown which DM patients in non-
SMBG subgroup were associated with poor glycemic control and  chronic complications (47). 
Various studies also support, in which SMBG has been shown to be associated with better 
glycemic control, improved medication compliance and increased the frequency of visit to 
health institution (47, 48).  
 
A cross-sectional study carried out among type 2 DM patients in India and observed that male 
sex was found to be a risk factor for poor glycemic control (49). Low level of education was 
also another factor which negatively affects blood glucose control among DM patients (49).  
 
A cross-sectional study conducted to assess the determinants of loss of glycemic control among 
patients with DM in Basrah, Iraq. In the study, the less educational level was found to be one 
of the contributing factors for poor  glycemic control (50). The result was also supported by 
similar studies carried out in Jordan (38), and Spain (51).  
 
A Prospective cohort study conducted to assess determinants of loss of glycemic control in 
patients with type 1 DM in Iraq. The study found that lower age to be a contributing factor to 
poor  glycemic control (50). Similar results were reported in Patient characteristics do not 
predict poor glycemic control in type 2 DM patients treated in primary care in Netherlands 
(52) and a longitudinal study conducted in Predictors of glycemic control among patients with 
Type 2 DM in  San Diego, USA (53).  
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A cross-sectional study conducted to assess the association between DM metabolic control and 
drug adherence in an indigent population in Virginia, USA revealed that better metabolic 
control was independently associated with increasing age (54). Similar findings were also 
observed in another USA study conducted in Medication adherence and achievement of 
glycemic targets in ambulatory type 2 DM patients (55). 
 
A cross-sectional study conducted on factors associated with poor glycemic control among 
patients with type 2 DM in Jordan. The study found that poor glycemic control was more 
common among patients who did not practice any physical activity (38). Similarly, a study 
conducted on Medication adherence and achievement of glycemic targets in ambulatory type 
2 DM patients in the USA, on the other hand, revealed that an increase in physical activity was 
found to be associated with a decrease in HbA1c levels of more than 1 percentage point (55). 
This was supported by studies and reports coming from Canada a controlled clinical trials  on 
Effects of exercise on glycemic control and body mass in  type 2 DM (56) and a similar study 
conducted in the USA on exercise and 24-h glycemic control: equal effects for all type 2 DM 
patients (57).  
 
A cross-sectional study conducted to assess dyslipidemia among DM patients in Hawssa, 
Southern Ethiopia. The study found that, higher mean serum levels of LDL cholesterol, total 
cholesterol, and triglycerides were significantly associated with a poor glycemic control in 
patients with diabetes, which are well known risk factors for CVD among DM patients (58). 
Similarly, study conducted in Jordan found that DM was more likely to be poorly controlled 
among those with increased duration of DM, lower level of education, higher BMI, 
hypercholesterolemia, hypertriglyceridemia, and elevated LDL (59). But was not consistent 
with cross sectional population study finding from the UK (60). 
 
A hospital based cross-sectional study conducted in Hawassa South Ethiopia, 2013; the study 
revealed that DM patients who did not perform self-monitoring of blood glucose were 15.22 
times more likely to have chronic complications than those who performed self-monitoring of 
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blood glucose. The study participants perform SMBG once per week and most of them were 
insulin treated DM patients (61) 
 
A cross-sectional study conducted to assess Self-Care behavior among Patients with DM in 
Harari, Eastern Ethiopia. The study found that income was one of the factors that affect self-
care behavior and lead to poor glycemic control. High and medium income patients were less 
adherent to self-care than low income patients; this may be due to high income patients may 
have riskier life style than low-income respondents (62).  
A cross-sectional study conducted to assess level of sustained glycemic control and associated 
factors among patients with DM in Gonder, Ethiopia. The study reported follow-up visit for 
the last 6 months showed that increased frequency of hospital visits was negatively associated 
with poor glycemic control (AOR =0.13; 95% CI =0.03, 0.59) among persons with Type 2 DM 
(44).  
Generally, in different kinds of literatures Poor glycemic control was found to be associated 
with sex, age, body mass index, hypertension, dyslipidemia, and duration of DM. Also, the 
glycemic level of the patients was possibly affected by self-management behaviors such as 
diet, exercise, and SMBG. 
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1.4 SIGNIFICANCE OF THE STUDY 
This study provides information about the current glycemic status of both glucometer user and 
non-glucometer user DM patients. This may allow for assessment of therapy and guiding 
adjustments in diet, exercise, and medication in order to achieve optimal glycemic control. 
This study also helps DM patients to improve the practical behaviors, testing blood glucose 
levels at home or SMBG is a valuable diabetes management tool. The study also facilitates 
regular testing and recording of blood glucose level that can help for DM patients to monitor 
the effects of healthy lifestyle choices. 
 
Moreover, this study provides evidence for evaluating how the DM patients control or monitor 
their blood glucose level activity depending on the laboratory tests; Due to these DM patients 
adjust their treatment plan and better control on management of DM. In addition to these, 
information generated from this study uses for interested bodies for further investigation to 
develop appropriate preventive and control strategy. Finally, Ayder Compressive Specialized 
Hospital and others health institutions can use this result for improving their services for DM 
patients. It also helps to encourage good services and expand their services especially 
laboratory facilities like HbA1c tests. 
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2. OBJECTIVE 
2.1 General objective 
 To assess Glycemic control and its associated factors among glucometer user and non-
user DM patients at Ayder Comprehensive Specialized Hospital, Mekelle, Northern 
Ethiopia. 
2.2 Specific objectives 
 To assess the overall prevalence of poor  glycemic control among DM patients  
 To compare glycemic control of DM patients between glucometer user and non-user  
as POCT 
 To identify  associated factors of poor glycemic control among DM patients  
Hypothesis 
There is a difference in glycemic control among glucometer user and non-user DM patients as 
POCT. 
 
 
 
 
 
 
 
 
 
 12 
 
3. MATERIALS AND METHODS 
3.1 Study area 
This study was conducted in Mekelle town, Tigray region, Northern part of Ethiopia. It is 
located around 780 kilometers from Addis Ababa, the capital city of Ethiopia. Based on the 
2009 Census conducted by the Central Statistical Agency of Ethiopia, this town has a total 
population of 215,914 people (104,925 men and 110,989 women).The city has one referral 
hospital , three general hospitals, nine health centers  and several private clinics and for-profit 
hospitals. The study was conducted at Ayder comprehensive specialized hospital, which is the 
second largest hospital in Ethiopia. It has 500 beds. It serves up to 8 million populations in its 
catchment areas of the Tigray region, North-eastern Amhara and Northern Afar regions. The 
hospital became functional before 8 years ago. It has four major departments and other 
specialty units. DM ambulatory clinic unit is one of the specialty units of the hospital, which 
provides medical services for registered DM patients. It also serves as a teaching hospital of 
the College of Health Sciences which was established under Mekelle University in 2003. 
3.2 Study design and period 
A prospective comparative cross-sectional study was conducted on DM patients from March 
1 to April 30, 2017.  
3.3 Population 
3.3.1 Source population 
All adult type I and type II DM patients following their medical care in Ayder Comprehensive 
Specialized Hospital.  
3.3.2 Study population 
All type I and type II DM patients ≥ 18 years old on follow up who fulfill the inclusion criteria 
in Ayder Comprehensive Specialized Hospital that visited DM clinic during the study period. 
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3.4 Inclusion criteria 
All type I and type II DM patients aged ≥18 years and who were glucometer user and non-
glucometer user as POCT. Patients using glucometer as POCT ≥ 6 months were also included 
in the study as adequate time needs for assessing adherence. 
3.5 Exclusion criteria 
 Critically ill patients and unable to participate in the interview 
 Patients with severe mental illness  
 Newly diagnosed DM patients   
 Other chronic diseases (Thyroid dysfunction, AIDS, Liver problem) 
3.6 Variables 
3.6.1 Dependent variable 
 Glycemic control  
3.6.2 Independent variables 
 Socio-demographic: age, sex, educational status, occupation, income, marital status, 
residence, and  family history of DM  
 Clinical characteristics and others associated factors: type of DM, duration of DM, type 
of treatment, Blood pressure, lipid profile, Body Mass Index, alcohol consumption, 
cigarette smoking and frequency of visiting in DM clinics.  
3.7 Sample size and sampling technique 
The sample size was determined using the difference between two population means with 
specified precision by OpenEpi version 2.3 statistical software formula based on the following 
assumptions:  the mean and SD of SMBG and non-SMBG group HbA1c were (9.5,2.4) and 
(10.5,3.1) respectively from a study conducted in the USA (63). The desired degree of 
precision was 5%, 95% confidence interval and for 90% power value is 1.28. An equal number 
of the sample was taken from each glucometer users and non-glucometer users. So that a total 
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sample was (168+168) = 336. Both glucometer users and non-users DM patients were enrolled 
in the study by using age and gender matched quota sampling technique.  
3.8 Data collection and laboratory methods 
Patients were given an orientation on the protocol and specific details concerning participation 
in the study. Data was collected by trained nurses; interviewing eligible participants using a 
pretested and structured questionnaire. The questionnaire includes questions intended to 
collect data about socio-demographic characteristics and clinical characteristics.  
Anthropometric measurements were taken using standardized techniques and calibrated 
equipment by trained nurses. Patients were weighed to the nearest 0.1 kg. Height was measured 
using a stadiometer. Every patient was made aware of the fasting requirement for a minimum 
of 8 hours prior to the laboratory test. Verbal confirmation was obtained prior to the blood test. 
Information about Type 1 and Type 2 DM was collected from the hospital chart by data 
collector nurse.  
Five milliliters of venous blood was drawn from each volunteer patient using a disposable 
plastic syringe by senior laboratory technologist. About two milliliters of venous blood poured 
into EDTA test tube for the determination of HbA1c. The HbA1c was measured by 
HumaMeter A1C analyzer (HUMAN Diagnostics, Germany).  About three milliliters of 
venous blood poured into Serum Separate Test tube and then centrifuged after it has been 
clotted. Serum was kept in the refrigerator till used. Serum FBS and lipid profile were 
measured by ABX PENTRA 400 clinical chemistry analyzer (HORIB ABX Diagnostics, 
France), according to the manufacturer’s procedures in ACSH central laboratory.  
 
Method 
GOD-PAP Enzymatic Colorimetric (HORIB ABX Diagnostics, France) and CHOD-PAP 
Enzymatic Colorimetric (HORIB ABX Diagnostics, France) methods were used for 
determination of blood glucose and lipid profiles, respectively. 
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Principle for determination of HbA1c 
The Humameter A1c regent KIT combines the chemical binding of boronate to glycated 
hemoglobin with the fluorescent quenching effect that this binding exerts on a fluorescent 
marker bound to the boronate molecule. The total hemoglobin concentration is determined 
from the initial decrease in the fluorescent signal. The fluorescent boronate conjugate binds to 
the glycated hemoglobin, which is measured by monitoring a decrease in the fluorescence of 
the active ingredient. The ratio of glycated hemoglobin to total hemoglobin is determined and 
the result is presented in up to two user selectable units: % DCCT (Diabetes control & 
complication Trial),mmol/mol IFCC (international Federationof clinical Chemistry). 
Mmol/mol= (% DCCT-2.15)*10.929 
In accordance with  ADA guidelines, glycemic status was categorized as good glycemic 
control if HbA1c <7% and poor glycemic control if HbA1c ≥7% (64), abnormal lipid profile 
was defined as Total Cholesterol ≥200 mg/dl, HDL-c <40mg/dl for male,  HDL-c <50 mg/dl 
for female, LDL-c ≥130 mg/dl, and Triglyceride ≥150mg/dl (64).  
3.9 Data management and quality control 
Two nurses and two medical laboratory technologists together with the principal investigator 
were involved in the data collection. One of the laboratory technologists with principal 
investigator acted as supervisor. Both the data collectors and supervisor were trained for one 
day to keep uniformity of the data collection process, blood specimen collection, processing, 
and analysis. Before actual data collection, the questionnaire was pre-tested on 5% volunteer 
patients to check clarity, acceptability, and consistency of the structured questionnaire in Qiuha 
hospital. Necessary corrections were taken before the actual data was collected. Blood samples 
that passed acceptable criteria by the laboratory Standard Operational Procedure were included 
in the study.   
To produce quality results, the standard operation procedure and manufacturer’s instructions 
were strictly followed. All samples were analyzed by senior medical laboratory Technologist. 
The automation was calibrated using an appropriate calibrator.  Quality control materials 
(Control N and Control P) were run at least once each day to verify each procedure. The 
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frequency of quality controls and the confidence intervals were corresponding to laboratory 
guidelines. The results were within the range of the defined confidence limits (within ±2SD). 
For those results were out of these confidence limits, the laboratory personnel were taken 
corrective action based on established procedure before reporting.  
3.10 Data analysis and interpretation 
All the data was cleaned, edited, coded and analyzed using SPSS version 20 statistical package. 
Frequencies and cross tabulations were used to summarize descriptive statistics. Independent 
t-tests were used to compare the mean of Clinical characteristics between glucometer user and 
non-user of study participants. Categorical and continuous variables were described as 
proportions and mean respectively. Multivariable logistic regression analysis was employed 
by selecting only variables with P-value <0.2 in the bivariate analysis. A multivariable logistic 
regression analysis was done to see the association between the independent variable and 
outcome variables. Odds ratio with 95% C.I was used for measuring the strength of association. 
P value < 0.05 was used to determine level of statistical significance 
3.11 Result dissemination plan 
The result of the study will be disseminated to Ayder comprehensive specialized hospital, 
Regional and zonal health office and also to the University of Gondar, College of Medicine 
and Health Sciences, School of Biomedical and Laboratory Sciences, Department of Clinical 
Chemistry. Results of this study will be disseminated through publication, presentation on 
annual scientific conferences and seminars.  
3.12 Ethical consideration 
Ethical clearance was obtained from Ethical Review Committee of School of Biomedical and 
Laboratory Sciences, University of Gondar. Permission was obtained from Ayder 
Comprehensive Specialized Hospital medical director to conduct the study. After informing 
about the objective of the study and the confidentiality of the data, written consent was taken 
from all study participants. To ensure confidentiality of data, study participants were identified 
using codes and unauthorized persons were not having access to the collected data. 
 17 
 
3.13 Operational definition 
 Hypertension: defined as People with systolic/diastolic blood pressure levels ≥130/80 
mmHg or who were on antihypertensive medication. 
 Body mass index:  categorized as if underweight if BMI<18 Kg/m2, normal if BMI 
was 18-25 kg/m2, overweight if BMI  was 25–29.9 kg/m2, and obese if BMI was ≥30 
kg/m2  
  Good glycemic control: defined as  HbA1c <7%  
  poor glycemic control: defined as HbA1c ≥7%  
 Abnormal lipid profile: defined as Hypercholesterolemia refers to a total cholesterol 
level ≥200 mg/dl. HDL was considered low when the level is <40 mg/dl in males and 
<50 mg/dl in females. LDL was considered high when the level is ≥130 mg/dl. 
Hypertriglyceridemia refers to a level ≥150 mg/dl.  
 Low income: respondents whose income level is below the 25% Inter-Quartile 
percentiles (IQP) 
 Medium income: defined as whose income level is between 25% -75% IQP 
 High income: defined as respondents whose income level is equal to or above the 75% 
IQP 
 Self-monitoring blood glucose (glucometer user): defined as participants performed 
home glucose monitoring for 5 days or more per week and at least check their blood 
glucose level once per day at home for the last 6 months. 
 Non-glucometer user: defined as participants not performed home glucose monitoring 
(no their own glucometer).    
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4. RESULT 
 
4.1 Socio demographic characteristics of study participants  
A total of 336 DM participants participated in this study; of these, 168 (50%) were glucometer 
users and the rest were non-users. One hundred sixty (47.6%) were at the age range of 45-64 
years. The mean age of participants were 49.25(±16.3) and 48.76(±15.9) among glucometer 
users and non-users respectively. The majority, 311 (92.6%) of study participants were urban 
residents; 139 (41.4%) were educated college and above level; 106 (31.6%) of participants 
were government employees and 163 (48.5%) had medium monthly income (Table 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 19 
 
Table 1: Socio-demographic characteristics of study participants in Ayder Comprehensive 
Specialized Hospital, Mekelle, Ethiopia, 2017 (n=336) 
  Variables                  Glucometer    
   User  Non-user: Total:  
 n (%)  n(%)  n (%)  P. value 
Age(years)      
<25 23(13.7) 23(13.7) 46(13.7)  
25-44  36(21.4) 34(20.2) 70(20.8)  
              45-64  79(47.0) 81(48.2) 160(47.6)       .994 
65+  30(17.9) 30(17.9) 60(17.9) 
Sex      
Male  89(53.0) 88(52.4) 177(52.7)       1.00 
Female  79(47.0) 80(47.6) 159(47.3)  
Residence      
Urban  162(96.4) 149(88.7) 311(92.6)       .013* 
Rural  6(3.6) 19(11.3) 25(7.4)  
Educational status      
              Unable to read and write  12(11.9) 29(17.3) 41(12.2)  
Write and read  10(6.0) 7(4.2) 17(5.1)  
Primary   30(17.9) 29(17.3) 59(17.5)        .008* 
Secondary  34(20.2) 46(27.4) 80(23.8)  
College and above  82(48.8) 57(33.9) 139(41.4)  
Occupation       
Student   20(11.9) 21(12.5) 41(12.2) 
Government employee  59(35.1) 47(27.9) 106(31.6)            .029* 
Private  19(11.3) 31(18.5) 50(14.9)  
Merchant  20(11.9) 8(4.8) 28(8.3)  
Unemployed  14(8.3) 13(7.7) 27(8.0)  
Housewife   24(14.3) 23(13.7) 47(14.0)  
Monthly income      
Low  33(19.6) 56(33.3) 89(26.5) <0.001* 
Medium  77(45.8) 86(51.2) 163(48.5)  
High  58(34.5) 26(15.4) 84(25.0)  
Has family history of DM      
Yes  55(32.7) 36(21.4) 91(27.1) . 027* 
No  113(67.3) 132(78.6) 245(72.9)  
Marital status      
Single  28(16.7) 26(15.5) 54(16.1)  
Married  105(62.5) 120(71.4) 225(67.0) .247 
Divorced  16(9.5) 11(6.5) 27(8.0)  
Widowed  19(11.3) 11(6.5) 30(8.9)  
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4.2 Clinical characteristics and anthropometric measurements of study participants by 
glucometer use  
Overall 208(61.9%) of the study subjects had poor glycemic control. The poor glycemic 
control was significantly higher in non-glucometer user 120 (71.4%) than glucometer user 88 
(52.4%) (P-value <0.001).  
About 264 (78.6%) were type-II DM subjects. More than half of males 98 (55.4%) had low 
value of high-density lipoprotein (HDL). About 198(58.9%) study subjects had average FBS 
≥130mg/dl (P-value=0.020 and 210(62.5%) study subjects were visited DM clinics greater 
than or equal to 6 times within six months (P=0.032). (Table2). 
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Table 2: Clinical characteristics of study participants in Ayder Comprehensive Specialized Hospital, 
Mekelle, Ethiopia, 2017 (n=336) 
Variables           Glucometer  
 User  Non-user               Total:    
  n(%)  n(%) n(%)            P. value 
Glycemic control     <0.001* 
Poor (HbA1c ≥ 7%) 88(52.4) 120(71.4) 208(61.9)  
Good (HbA1c <7%) 80(47.6) 48(28.6) 128(38.1)  
BMI     
Low (<18) 7(4.2) 4(2.4) 11(3.3)  
Normal (18-25) 85(50.6) 106(63.1) 191(56.8)  
Overweight (25-29) 62(36.9) 48(28.6) 110(32.7)  
Obese (>=30) 14(8.3) 10(5.9) 24(7.1)  
Duration of DM    0.913 
≤7years 90(53.6) 92(54.8) 182(54.2)  
>7 years 78(46.4) 76(45.2) 154(45.8)  
Number of DM clinic visits    .032* 
<6 times / 6 months 53(31.6) 73(43.4) 126(37.5)  
≥6 times/6 months 115(68.4) 95(56.6) 210(62.5)  
Triglyceride    .743 
Normal(<150) 93(55.4) 89(53.0) 182(54.2)  
High (≥150) 75(44.6) 79(47.0) 154(45.8)  
Total cholesterol    0.361 
Normal (<200) 126(75.0) 134(79.8) 260(77.4)  
High (≥200) 42(25.0) 34(20.2) 76(22.6)  
HDL males(n=177)    0.827 
Normal (≥40) 39(43.8) 40(45.5) 79(44.6)  
Low(<40) 50(56.2) 48(54.5) 98(55.4)  
HDL females(n=159)    0.767 
Normal (≥50) 8(10.1) 7(8.8) 15(9.4)  
Low (<50) 71(89.9) 73(91.2) 144(90.6)  
LDL    0.482 
            Normal (<130) 134(79.7) 140(83.3) 274(81.6)  
High(≥130) 34(20.2) 28(16.7) 62(18.4)  
Type of DM    0.894 
Type I 37(22.0) 35(20.8) 72(21.4)  
Type II 131(78.0) 133(79.2) 264(78.6)  
Hypertension     0.230 
No  (<130/80mm/Hg) 78(46.4) 90(53.6) 168(50.0)  
Yes( ≥130 /80mm/Hg) 90(53.6) 78(46.4) 168(50.0)  
FBS    0.020* 
<130 mg/dl 80(47.6) 58(34.5) 138(41.1)  
≥130 mg/dl 88(52.4) 110(65.5) 198(58.9) 
OHA- Oral Hypoglycemic Agents          
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4.3 Comparison of the mean of Clinical characteristics of study participants   
The mean of HgA1C was significantly higher among non-glucometer users than glucometer 
users (8.4 ±2.24 vs. 7.68 ±1.95) (p-value<0.001). Likewise, the level of FBS was higher among 
glucometer non-users (176.2±71.7) than users (152.3 ±65.4) (p-value=0.002). However, the 
mean BMI was higher among glucometer users (24.6±3.6) than non-users (23.8±3.9) 
(P=0.047) (Table 3).  
Table 3: Comparison of the mean of Clinical characteristics by glucometer use of DM subjects 
based on independent t-test in Ayder Comprehensive Specialized Hospital, Mekelle, Ethiopia, 
2017. (n=336) 
Clinical Parameters Glucometer    
       User 
   (Mean ±SD)* 
  Non-user 
 (Mean± SD) 
T** P-value 
  HbA1c 
 Total Cholesterol  
       7.68±1.95 
       170.8 ±47.7 
8. 4±2.24 
166.6 ±44.13 
-3.306 
0.845 
.001 
.398 
Triglyceride         180.4 ±108.2 175.7 ±95.8 0.422 .674 
High density lipoprotein        37.7 ±8.9 37.7 ±8.8 -.049 .961 
Low density lipoprotein        95.6 ±34.4 93.9 ±33.9 0.455 .649 
Systolic blood pressure         127.7 ±13.1 125.7 ±13.0 1.362 .174 
Diastolic blood pressure         77.2 ±8.3  76.7 ±9.2 .528 .598 
Duration of  DM 
Fasting blood sugar 
 Body mass index  
       7.79 ±4.89 
       152.3 ±65.4  
        24.6±3.6 
 7.87±5.48 
 176.2±71.7 
  23.8±3.9 
 0.282 
-3.193 
  0 .238 
 .883 
.002 
 .047 
*Mean and standard deviation, **Independent t-test, HbA1c- Glycated Haemoglobin A1c 
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4.4 Correlation between lipid profiles and Glucose with HbA1c level  
Pearson correlation test showed that HbA1c significantly correlate positively with T. 
cholesterol (r=0.283, P<0.001), Triglyceride (r=0.252, P<0.001), LDL(r=0.254, P<0.001), and 
glucose (r=0.906, P<0.001). Whereas, negatively correlated with HDL level (r= -0.041, 
P=0.459) but not significant (Table 4). 
Table 4: Pearson Correlation tests between lipid profiles and Glucose with HbA1c level among 
DM subjects in Ayder Comprehensive Specialized Hospital, Mekelle, Ethiopia, 2017 (n=336). 
Variables  T. cholesterol Triglyceride *LDL *HDL Glucose 
HbA1c Correlation (r) 
Coefficient 
0.283** 0.252** 0.254*
* 
-0.041 0.906** 
P. value 0.000 0.000 0.000 0.459 0.000 
**Correlation significant P<0.05, *LDL- Low Density Lipoprotein, *HDL- High Density 
Lipoprotein 
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4.5 Factors associated with poor glycemic control  
It was found that age, income, the number of visits in DM clinics, the level of triglyceride, 
level of low density lipoprotein and non-glucometer users were significantly associated with 
poor glycemic control. Participants who were at age group less than 25 years had higher odds 
of poor glycemic control compared to greater than or equal to 25 years old. Those who were 
in medium income category had 2.5 times (AOR=2.5; 95%CI (1.3, 4.89)) higher odds of poor 
glycemic control than who were on low income category.  Participants who were visited DM 
clinics less than 6 times had 0.55 times(AOR=0.55; 95%CI (0.3, 0.94))  higher odds of  poor 
glycemic control compared to more or equals to 6 times visited in the past six months. 
Participants with higher triglyceride and LDL level had 2.29 times (AOR=2.29; 95%CI (1.25, 
4.2)) and 4.1 times (AOR=4.1; 95%CI (1.48, 11.4)) higher odds of poor glycemic control than 
normal counterparts (triglyceride<150 and LDL<130) respectively.  Non-users of glucometer 
for self-monitoring had 2.7 times (AOR=2.7; 95%CI (1.58, 4.64)) higher odds of poor 
glycemic control than those who use a glucometer for self-monitoring (Table 5). 
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Table 5: Factors associated with poor glycemic control among DM subjects in Ayder Comprehensive Specialized 
Hospital, Mekelle, Ethiopia, 2017 (n=336). 
 
Variables           Glycemic control                   
 Good: n (%)  
(HbA1c <7%) 
Poor: n (%)  
(HbA1c≥7%) 
COR 95%(CI) AOR95%(CI)       P.val 
Age (years)     
65+ 26(43.3) 34(56.7) 1 1 
45-64 62(38.8) 98(61.2)  0.69(0.3, 1.39)*                                         0.24(0.09,0.6)**    .007     
25-44 26(37.1) 44(62.9)  0.74(0.3,1.39)* 0.25(0.09,0.67)**   .010 
≥24 14(30.4) 32(69.6) 0.57(0.2, 1.29) *           0.22(0.08,0.61)**  
.009   
Residence     
Rural 6(24.0) 19(76.0) 1  
Urban 122(39.2) 189(60.8) 2.04(0.7, 5.26)            1.78(0.59,5.3)        .064 
Monthly income     
Low 38(42.7) 51(57.3) 1 1 
Medium 51(31.3) 112(68.7) 1.64(0.96, 2.79)            2.5(1.3,4.89)**      .002 
High 39(46.4) 45(53.6) 0.86(0.47,1.57)            1.69(0.74,3.81)      .217 
Number of visits per 
last 6 months 
    
≥6 times  95(45.2) 115(54.8) 1 1 
<6 times 33(26.2) 93(73.8) 0.49(0.2, 0.69) **        0.55(0.3,0.94)*    .034 
Alcohol Intake     
No 111(41.6) 156(58.4) 1 1 
Yes 17(24.6) 52(75.4) 2.2(1.1, 3.96)*           1.5(0.75,3.0)         .343 
Triglyceride     
          Normal (<150) 89(48.9) 93(51.1) 1 1 
          High(≥150) 39(25.3) 115(74.7) 2.8(1.77,4.49)***       2.29(1.25,4.2)**   .005 
LDL     
           Normal (<130) 120(43.8) 154(56.2) 1 1 
           High( ≥130) 8(12.9) 54(87.1) 5.26(2.4,11.5)***        4.1(1.48,11.4)**    .001 
Glucometer use     
Yes 80(47.6) 88(52.4) 1 1 
               No 
T. cholesterol 
           Normal (<200)                                                              
            High (≥200) 
Hypertension 
                    No  
                    Yes    
48(28.6) 
 
114(43.8) 
14(18.4) 
 
57(33.9) 
71(42.5) 
120(71.4) 
 
146(56.2)    
62(81.6) 
 
111(66.1)              
97(57.7) 
2.3(1.45,3.57)***        
 
1
3.45(1.84,6.49)***              
 
1 
1.4(.96,2.219) *            
2.7(1.58,4.64)*** .000     
 
1 
1.2(0.490,2.94)    .690 
 
1 
1.4(.83,2.57)        .189 
COR: Crude Odds Ratio; AOR: Adjusted Odds Ratio; Significant at: * p -value<0.05; **p-value<0.01; ***p-
value<0.001; LDL- Low-Density Lipoprotein. 
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5. DISCUSSION 
Diabetes is a chronic disease significantly affecting the quality of life of many people (36). Its 
prevalence rate is increasing in epidemic proportion in the globe (65).  DM incidence is 
predicted to increase from 2.8% in 2000 to 4.4% in 2030 across the world of all age-groups 
(65). In the present study, glycemic control and its associated factors among glucometer user 
and non-glucometer user were evaluated in DM Subjects. 
In this study, 208(61.9%) of the study subjects were poor glycemic control.  This finding was 
comparable to  studies conducted among DM subjects in Gondar Referral Hospital, Ethiopia, 
64.7% (44), Jima, Ethiopia 58.2% (45) and Jordan 65.1% (38). However, the current study was 
lower than other studies conducted in India, Cameroon and Saudi Arabia (74%, 78.6%, and 
78% respectively) (39, 40, 49).  
 
The differences in variation may be explained by the differences in study designs, 
characteristics of the study populations, and the types of treatment facilities. Furthermore, 
differences in race and ethnicity of the studied populations, dosage for oral medication, 
compliance with regimens, self‑monitoring of blood glucose, and socioeconomic status may 
differ by race/ethnic group leading to greater improvements in control in some groups but not 
in others. 
 
Furthermore, this study showed a higher proportion of poor glycemic control than the study 
conducted  in Ambo Hospital, Ethiopia, which showed 50%  poor glycemic control (46). The 
discrepancy between the findings of the current study and Ambo might be explained by the 
fact that our study used the recommended test for glycemic control, the HbA1c test, whereas 
the Ambo study used the FBG test for Glycemic control. Moreover, the Ambo study included 
only Type 2 DM patients (46). 
In this study Poor glycemic control was significantly higher in non-glucometer users (71.4%) 
than glucometer users (52.4%) (P-value <0.001). This finding was consistent with the studies 
conducted in Jamaica and Jordan which showed the poor glycemic control proportion among  
glucometer users were 52.5% (43) and 51.1% (26) respectively. Similarly, the poor glycemic 
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control among non-glucometer users was higher than glucometer-users in this studies, in 
Jamiaica 61.9% (43) and Jordan 71.4% (26). However, in this study, the proportion of poor 
glycemic control among glucometer user was higher than a study conducted in Italy 38.1% 
(42). The difference might be explained, socioeconomic status may influence diabetes 
management and control since it is often associated with access to health care, healthcare 
utilization, use of medication, and access to good nutrition. 
The poor glycemic control found in this study was similar to the previous study in Jordan 
which was 71.4% among non-glucometer users (26). However, the current study was higher 
than a study conducted in Jamaica 61.9% among non-glucometer users (43). On the other hand, 
this study was lower than other study reported the proportion of patients with poor glycemic 
control among non-glucometer user in Italy 80% (42). The difference might be explained due 
to the difference in study design, lifestyle, and socioeconomic status may differ by race/ethnic 
group leading to greater improvements in control in some groups but not in others.   
In this study, non-glucometer users were significantly associated with the poor glycemic 
control 71.4%. This finding is similar to a  study conducted in Germany (47), Jordan(38), 
Jamaica (43)  and Hawasa, South Ethiopia (61). Various studies have shown that glucometer 
use was associated with better glycemic control, improved medication compliance and 
increased the frequency of visit to health institution (47, 48). However, the controversial result 
was reported from Italy where SMBG frequency ≥ 1 time per day has been shown significantly 
associated with higher HbA1c, distress, worries and depressive symptoms in non-insulin 
treated DM patients (66). 
In this study, Participants who were at age group less than 25 years had higher odds of poor 
glycemic control compared to greater than or equal to 25 years old. The finding that younger 
age was associated with poor glycemic control is congruent with similar studies conducted San 
Diego, USA(53), Netherlands(52), Iraq(50) and Gondar, Ethiopia(44). They might be more 
likely to pay no attention to DM as being important and could be less adherent to medication, 
lifestyle and diet limitations. On the contrary, older patients might be more motivated to take 
care of their DM and be more compliant with their medication, regular physical activity and 
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eat healthy low-calorie diet. Diabetes self-management intervention may help these target 
patients to maintain their health and quality of life since effective self-management and quality 
of life are the key outcomes of diabetes self-management education and support. 
Like other factors, in this study, DM participants that were in medium income category had 
2.5times (AOR=2.5; 95%CI (1.3, 4.89)) higher odds of poor glycemic control than who were 
on low income category. This finding was similar to a study done in Hariri, Ethiopia (62). This 
may be due to medium income DM patients were less adherent to self-care than low-income 
patients. 
However, in this study, Participants who were visited DM clinics less than 6 times had 0.55 
times(AOR=0.55; 95%CI (0.3, 0.94)) higher odds of  poor glycemic control compared to more 
or equals to 6 times visited in the past six months. This study was consistent to study conducted 
in Gondar Referral Hospital (44). This indicates that frequently visiting DM clinic has better 
counseling and teaching to DM patients, adherence to medication and lifestyle change. 
In the present study, high triglyceride and LDL level significantly associated with the poor 
glycaemic control. The finding was similar to a study conducted in Jordan (59) and Hawassa, 
Southern Ethiopia (58). This might be explained by the fact that chronic entry of fatty acids 
into b-cells (i.e., b-cell lipotoxicity) is believed to be involved in its pathogenesis and cause 
pancreatic b-cell failure resulting in poor glycemic control (67). 
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6. STRENGTHS AND LIMITATIONS 
6.1 Limitation of the Study 
Study Participants were from a single hospital-based specialty clinic, thus findings could not 
be generalized beyond this study site. 
6.2 Strength of the study 
This study determined HbA1-c test which is one of the primary techniques to assess the 
effectiveness of the management plan on glycemic control.  
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7. CONCLUSION AND RECOMMENDATIONS 
7.1 Conclusion 
In this study, a higher proportion of DM subjects had poor glycemic control (61.9%). The poor 
glycemic control was significantly higher in non-glucometer users (71.4%) than glucometer 
users (52.4%) for SMBG. The finding obtained from multivariate logistic regression analysis 
suggest that, age, income, the number of visits, the level of triglyceride, the level of low-density 
lipoprotein, and non-glucometer users were significantly associated with the poor glycemic 
control. In fact, glucometer use is associated with lower HbA1c and decreased odds of having 
poor glycaemic control.  
7.2 Recommendations 
 There should be periodic assessment of blood glucose monitoring among glucometer 
user and non-user DM patients. 
 Using glucometer for SMBG may, therefore, be useful in achieving glycemic control 
and should be considered by healthcare practitioners as part of DM management and 
initiate DM patients to use a glucometer for SMBG. . 
 Implementation of HbA1C measurement in the routine follow up of DM patients as 
a tool for estimation of the long-term diabetes control is highly recommended. 
 Further longitudinal studies should be done to identify determinant factors 
 The stake holders should be give attention for the availability of glucometers and 
strips with   affordable price for DM patients. 
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9. ANNEXES 
Annex 1 .English version of information sheet, consent and questionnaire 
Annex 1.1 Subject information sheet 
Greetings: 
My name is ___________________ I am working with Seifu Mideksa who is currently a post 
graduate student in University of Gondar, School of Biomedical and Laboratory Sciences, 
Department of Clinical Chemistry. 
The objective of this study is to assess Glycemic control and its associated factors among 
glucometer user and non-user diabetes mellitus patients at Ayder Comprehensive Specialized 
Hospital, Mekelle, Northern, Ethiopia. The research is assessing these issues in DM patients 
like you thereby major factors contributing to anti-DM medication dose and blood glucose 
level control. You will be asked to fill a questionnaire that will help in investigating the issues. 
Then venous blood sample 3ml-5ml will be collected by laboratory technologist and the sample 
will be taken to the laboratory for serum glucose measurement and lipid profile. 
Risk during study: There is no risk and serious invasive procedure at the beginning as well as 
at the end of the study except a minimal pain during sample collection. 
Benefit/compensation: In taking part to this study, you are not going to be compensated too, 
rather the findings from this study will enable us, we hope, to improve DM care outcomes in 
general, and hence you will be benefited then. Also, you will be know your current HbA1c, 
FBS, and lipid profile without any payment. 
It is only through chance that you became part of the study like others; otherwise, if you do not 
want to be part of the study, you can refuse to participate. In doing so, you will not going to 
lose any service that you are getting from the Hospital. I will be very grateful if you are going 
to be willing to participate in this study and hence we, together can do something positive 
towards DM care outcomes. Finally, it is my great pleasure to forward you deepest gratitude 
in advance for your kind cooperation you are going to have during the interview by giving your 
time with genuine information to me. Once again, I am assuring you, by any means, your 
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confidentially will not be broken and be kept secret and the data generated will be used for the 
purpose of this research only. 
Annex 1.2 Consent Form 
Considering the information you get from the general information sheet, Are you Comfortable 
to participate in this study? 1. If yes, I will continue   2. If no, I will skip to other participant 
after writing the reasons of refusal 
Respondent  
Signature ______________________Date__________________  
Interviewer  
Name____________________________________ Signature________________  
Questionnaires number_____________________  
Date of interview___________________ Starting time_________ Completed________  
Result of interview A) Completed B) Not completed C) Partially completed D) Refused  
 
For any information or question  
Contact person and address 
Name of PI: Seifu Mideksa 
Address: phone 0911911692/0914132251 
Email: seifumid2000@yahoo.com 
 
Advisors 
Mr. Habtamu Wondifraw (Msc)  
Address: phone 0910818289 
Email: habtamuw97@gmail.com 
 
 Mr. Sintayehu Ambachew (Msc)  
Address: phone 0938279709 
Email: sinte.ambachew@gmail.com 
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Annex 1.3 English versions Questionnaire 
Questionnaire Identification Number____________ 
Address: city/Sub city _______ Worda ________Medical Card Number__________ 
Title: Glycemic control and its associated factors among glucometer user and non-user diabetes 
mellitus patients  
No 1.Socio-demographic and 
clinical characteristics 
Response classification Code 
101 Sex of the respondents A. Male 0 
B. Female 1 
102 Age ---------------  
103 What is your last level of 
education?  
 
A. Unable to read and write 0 
B. Read and write 1 
C. Primary(Grade 1-8) 2 
D. Secondry(Grade 9-12) 3 
E. College and above 4 
104  What is your current 
occupation?  
 
A.Student 0 
B. Government employee 1 
C. Private enterprise 
 Employee 
2 
3 
D. Merchant 4 
E. Housewife 5 
 F. unemployed 6 
105 Residence  A. urban 0 
B. rural 1 
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106 How much income you earn 
Monthly? (Ethiopian Birr)--
-------- 
  
107 Marital status A. Single 0 
B. Married 1 
C. Divorced 
D. widowed 
2 
3 
108 Do you have history of DM 
in your family? 
      A. Yes 0 
      B  .No 1 
C. don’t know 3 
109 Types of DM A. Type I 0 
B. Type II 1 
C. Unknown 2 
110 Duration of DM in year 
______________ 
  
111 Types of diabetes 
management 
A. Insulin 0 
B. OHA/tabs 1 
C. Insulin & OHA 2 
D. Diet only 3 
112 Regular exercise      A .yes 0 
     B .No 1 
113 Do you drink alcohol?       A .Yes 0 
B. No 1 
114 Do you smoke cigarette? A. Yes 0 
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B. NO 1 
115 Do you have glucometer at 
home for SMBG? 
A. Yes   0 
 
B. No 1 
116 How many times did you 
visit DM clinic for the last 6 
months? 
_____________ 
 
 
 
    
Annex 1.4 Anthropometric measurements   code no. ________________ 
1. BMI   weight _______________kg 
Height ________________m 
 = W/H2  
________________________________Kg/m2             
          A. low                                B. Normal          C. over weight                  D. obesity 
2. Blood pressure BP _______________mm/hg    
Hypertensive   A. yes     B. No 
 
Annex 2.5 Laboratory test          code no.  ______________ 
1. Fast blood glucose(FBS)  ________________ 
                                         HbA1c ________________ 
A. good glycemic control  HbA1c <7% or FBS <130mg/dl   B. poor glycemic control 
HbA1c ≥ 7% or FBS ≥ 130mg/dl 
2. Lipid profile 
              Total cholesterol _______________ (≥200mg/dl) 
 
              Triglyceride       _______________ (≥150mg/dl) 
  
              HDL-C for male             _______________( <40mg/dl) 
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              HDL-C for female         ________________(<50mg/dl 
              LDL-C                            ________________ (≥130mg/dl) 
 
 Dyslipidemia           A. yes         B. No 
Name of data collector _________________ Signature __________ 
Name of Supervisor __________________    Signature ______________ 
 
 
Thank you very much for your giving your precious time and your collaboration! 
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Annex 2. Laboratory procedures and test principles 
Procedure for Determination of HbA1c, Glucose and lipid profile using HumaMeter A1c and 
Clinical chemistry analyzer 
1. Label tubes with the participants’ code number. (Labeling can also be done immediately 
after the specimen is obtained). 
2. Explain the blood drawing procedure to the participant and reassure 
3. Wear the rubber gloves and make the patient a comfortable position 
4. Prepare the syringe and needle 
5. Tie the tourniquet around the arm of the patient just above the bend in the elbow. The 
tourniquet should be positioned 7.5cm to 10cm above the puncture site 
6. Tell the patient to clench his/her fist 
7.  using the tip of the index finger examine the phlebotomy site, feel the vein, and decide 
exactly where to place the puncture 
8. Disinfect the phlebotomy site by swabbing the skin in small outward circles with alcohol 
swab or cotton wool soaked in isopropyl alcohol. Do not touch the prepared puncture site with 
your fingers after disinfecting the skin 
9. Insert the needle directly into the vein and withdraw venous blood of approximately 5ml   
transfer the blood in to EDTA test tube about 2ml for HbA1c test and about 3ml into SST test 
tube slowly for FBS and lipid profiles tests. 
10. Tell the patient to open his/her clenched fist  
11. Release the tourniquet  
12. Withdraw the needle from the vein and cover the puncture site cotton swab and hold (or 
have the subject hold) pressure at the puncture site for 3 minutes or until adequate haemostasis 
is visible. 
13. Properly discard the used materials in a safe container and tell the subject to do so if handled 
the cotton swabs to stop the bleeding 
14. The venous blood sample taken to the laboratory within 30 minutes and centrifuged at 
5000rpm for 5 minutes to obtain the serum 
15. Calibrate Chemistry Analyzer using calibrator and run the control N and control P 
16. Check the Quality control results whether passed or fails if passed 
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17. Test EDTA blood sample for HbA1c 
18. Test serum sample for FBS and lipid profile 
19. Record the result  
N.B. we were strictly follow standard operation procedures (SOPs) and Manufacturer’s 
instructions. 
The specimens were analyzed using PENTRA ABX 400 (Horiba ABX Diagnostics France) 
for FBS and Lipid profiles and HumaMeter A1c (HUMAN Diagnostics for HbA1c 
determination 
HbA1c 
Principle 
The Humameter A1c regent KIT combines the chemical binding of boronate to glycated 
hemoglobin with the fluorescent quenching effect that this binding exerts on a fluorescent 
marker bound to the boronate molecule . the total hemoglobin concentration is determined 
from the initial decrease in the fluorescent signal. The fluorescent boronate conjugate binds to 
the glycated hemoglobin, which is measured by monitoring a decrease in the fluorescence of 
the active ingredient. The ratio of glycated hemoglobin to total hemoglobin is determined and 
the result is presented in up to two user selectable units: % DCCT(Diabetes control & 
complication Trial),mmol/mol IFCC (international Federationof clinical Chemistry). 
Mmol/mol=(% DCCT-2.15)*10.929 
Clinical Significance 
HbA1c is formed in two steps by the nonenzymatic reaction of glucose with the N-terminal 
amino group of the -chain of normal adult Hb (HbA). The first step is reversible and yields 
labile HbA1c. This slowly rearranges in the second reaction step to yield stable HbA1c.  In 
erythrocytes the relative amount of HbA converted to stable HbA1c increases with the average 
concentration of glucose in the blood. The conversion to stable HbA1c is limited by the 
erythrocyte’s life span of approximately 100 to 120 days. As a result, HbA1c reflects the 
average blood glucose level during the preceding two to three months. HbA1c is thus suitable 
to monitor long-term blood glucose control in individuals with diabetes mellitus. More recent 
glucose levels have a greater influence on the HbA1c level. 
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The risk of diabetic complications, such as diabetic nephropathy and retinopathy increases with 
poor metabolic control. In accordance with its function as an indicator for the mean blood 
glucose level, HbA1c predicts the development of diabetic complications 
Testing Procedure: 
1. Check the temperature indicator on the box before taking a cartridge out. If red, do not 
use. 
2. Refrigerated cartridges should be warmed to room temperature for 10 minutes before 
use. 
3. When a cartridge package is opened, the cartridge must be used within one hour. 
 Check the cartridge and do not use it:  
o if the cartridge is damaged,  
o if the flexible cartridge pull-tab is loose or missing, or  
o If the desiccant is missing or loose desiccant particles are found inside the 
foil pouch. 
4. Room temperature must be between 150c and 30°c.  Do not test if temperature exceeds 
this range.  Room temperature must be recorded on the test log for each test that is 
done. 
5. Allow the instrument enough time to warm up at the beginning of the day. 
6. Pass cartridge through reader.  A beep sound indicates a successful scan 
7. Fill capillary holder with blood (1 microliter from EDTA blood).  Wipe outside of 
capillary tube.   
8. If blood contacts the plastic part of the capillary holder, discard the holder and use 
another one. 
9. Insert holder into the reagent cartridge with the rounded side of the holder to the 
outside. 
10. Hold the cartridge with the foil to the left, and insert cartridge into instrument until it 
snaps into place.   
11. Remove the tab and foil from the cartridge. 
12. Close the door on the instrument.  Reaction is completed in 6 minutes. 
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13. Read percent HbAlc before removing the cartridge.   
• The range of the instrument is 4 to 15.0%.   
• The result is displayed as percent HbA1c.   
• Results proceeded by a < sign indicates a level below the range and a > indicates a 
level above the range, and should be recorded as such.  
14. Record the result in the testing log, and in the patient’s chart.  All results are reported 
to the physician or advance practice nurse immediately. 
15. Remove the cartridge by pushing down on the gray tab while sliding the cartridge to 
the right, toward the gray tab—then lift the cartridge out of the instrument and discard 
it in a biohazard container. 
Calculations 
None.  The result is displayed as percent HbA1c. 
Reporting Results 
Reference Range:  4.2% to 6.5% HbA1c 
Good glycemic control if < 7% HbA1c according to ADA 
Poor glycemic control if ≥ HbA1c 7% according to ADA 
Glucose 
Principle of glucose oxidase method: Glucose level will be determined by an enzymatic 
spectrophotometric glucose oxidase method. The basic principle is that, Glucose is oxidized 
by glucose oxidase (GOD) enzyme to produce gluconate and hydrogen peroxide (H2O2). The 
H2O2 is then oxidatively coupled with 4 amino-antipyrene (4-AAP) and phenol in the presence 
of peroxidase (POD) enzyme to yield a red quinoeimine dye that is measured at 505 nm with 
a spectrophotometer. The absorbance at 505 nm is proportional to concentration of glucose in 
the sample. The method has linearity from bb0.0126 mmol/l (0.23 mg/dl) to 27.5 mmol/l (500 
mg/dl). 
                Glucose +2H2O + O2 GOD  Gluconate + H2O2  
                2H2O2 + 4-AAP+ Phenol POD Quinoeimine Dye + 4H2O  
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Absorbance of the colored solution is directly proportional to the glucose concentration when 
measured at 505 nm.  
Triglyceride 
Test principle: 
Enzymatic colorimetric method (GPO/PAP) with glycerol phosphate oxidase and 4 amino 
phenazone.b 
Triglycerides are hydrolyzed by lipoprotein lipase (LPL) to glycerol and fatty acids. Glycerol 
is then phosphorylated to glycerol-3-phosphate by ATP in a reaction catalyzed by glycerol 
kinase (GK). The oxidation of glycerol-3-phosphate is catalyzed by glycerol phosphate oxidase 
(GPO) to form dihydroacetone phosphate and hydrogen peroxide (H2O2). In the presence of 
peroxidase (POD), hydrogen peroxide affects the oxidative coupling of 4-chlorophenol and 4-
aminophenazone to form a red colored quinoneimine dye, which is measured at 512 nm. The 
increase in absorbance is directly proportional to the concentration of triglycerides in the 
sample. 
Triglycerides ⎯LPL→ glycerol + fatty acids 
Glycerol+ ATP⎯GK→ glycerol-3-phosphate + ADP 
Glycerol-3-phosphate + O2⎯GPO→ dihydroacetone  phosphate + H2O2. 
2H2O2 + 4-aminophenazone⎯POD→ quinoneimine dye + 4-chlorophenol+4H2O 
Cholesterol 
Test principle: 
Enzymatic colorimetric method (CHOD/PAP) with cholesterol esterase, cholesterol oxidase, 
and 4-aminoantipyrine. 
Cholesterol esterase (CE) hydrolyzes cholesterol esters to form free cholesterol and free fatty 
acids. Cholesterol oxidase (CHOD) then catalyzes the oxidation of cholesterol to form cholest-
4-ene-3-one and H2O2. In the presence of peroxidase (POD), the hydrogen peroxide formed 
affects the oxidative coupling of phenol and 4-amino-antipyrine(4-AAP) to form a red colored 
quinoneimine dye. The color intensity of the red quinoneimine dye formed is directly 
proportional to the cholesterol concentration. It is determined by measuring the increase in 
absorbance at 520 nm. 
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Cholesterol esters + H2O CE→ cholesterol + fatty acids 
Cholesterol + O2 CHOD→ cholest-4-ene-3-one + H2O2 
2H2O2 + 4-AAP+ phenol POD→ quinoneimine dye +4 H2O 
HDL-Cholesterol: 
Test principle: 
Homogeneous enzymatic colorimetric assay 
In the presence of magnesium sulfate and dextran sulfate, water-soluble complexes with LDL, 
VLDL, and chylomicrons are formed which are resistant to Poly Ethylene Glycol (PEG)-
modified enzymes. The cholesterol concentration of HDL-cholesterol is determined 
enzymatically by cholesterol esterase and cholesterol oxidase coupled with PEG to the amino 
groups (approximately 40%). Cholesterol esters are broken down quantitatively into free 
cholesterol and fatty acids by cholesterol esterase. In the presence of oxygen, cholesterol is 
oxidized by cholesterol oxidase to 4-cholestenone and hydrogen peroxide. The color intensity 
of the blue quinoneimine dye formed is directly proportional to the HDL-cholesterol 
concentration. It is determined by measuring the increase in absorbance at 583 nm. 
HDL-cholesterol esters + H2O⎯PEG cholesterol esterase→ HDL-cholesterol + RCOOH 
HDL-cholesterol + O2⎯PEG-cholesterol oxidae→4-cholestenone + H2O2 
2 H2O2 + 4-aminoantipyrine + HSDA+ Hperoxidase→ purple blue pigment + 4 H2O 
LDL-Cholesterol: 
Test principle: 
Homogeneous enzymatic colorimetric assay 
This automated method for the direct determination of LDL-cholesterol takes advantage of the 
selective micellary solubilization of LDL-cholesterol by a nonionic detergent and the 
interaction of a sugar compound and lipoproteins (VLDL and chylomicrons). When a detergent 
is included in the enzymatic method for cholesterol determination (cholesterol esterase and 
cholesterol oxidase coupling reaction), the relative reactivities of cholesterol in the lipoprotein 
fractions increase in this order: HDL < chylomicrons < VLDL < LDL. In the presence of 
Mg++, a sugar compound markedly reduces the enzymatic reaction of the cholesterol 
measurement in VLDL and chylomicrons. The combination of a sugar compound with 
detergent enables the selective determination of LDL-cholesterol in the serum. In the presence 
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of oxygen, cholesterol is oxidized by cholesterol oxidase to 4-cholestenone and hydrogen 
peroxide. The color intensity of the blue quinoneimine dye formed is directly proportional to 
the LDL-cholesterol concentration. It is determined by measuring the increase in absorbance 
at 583 nm. 
LDL-cholesterol ester + H2O⎯detergent⎯cholesterolesterase→ cholesterol + free fatty 
acid (selective micellarysolubilization) 
LDL-cholesterol + O2⎯cholesterol oxidase→4-cholestenone+ H2O2 
2 H2O2 + 4-aminoantipyrine + HSDA+ H+H2O2⎯peroxidase→ purple blue pigment +5 
H2O 
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Annex 3. Amharic version participants information sheet, consent and questionnaire  
ጎንደር ዩኒቨርሲቲ፤ ህክምናና ጤና ሳይንስ ኮሌጅ፤ ባዮሜዲካልና ላቦራቶሪ ሳይንስ ት/ቤት፤ ክሊንካል  ኪሚስትሪ  ት/ክፍል  
የተጠያቂው / መላሾች የመረጃ ቅፅ እንደምን አደሩ / ዋሉ ፡፡ ስሜ ------------------------------- ይባላል:: ከዚህ 
የመጣሁት የጎንደር ዩኒቨርሲቲ፤ ህክምናና ጤና ሳይንስ ኮሌጅ፤ ባዮሜዲካልና ላቦራቶሪ ሳይንሠ ት/ቤት፤ ክሊንካል  
ኬሚስትሪ ት/ክፍል  የሁለተኛ ዲግሪ ተማሪ የሆነውን ሰይፉ ሚደቅሳ ወከዬ ነው፡፡ ሁለተኛ ዲግሪዉን ለመመረቅ የስኳር 
ህመምተኞች በደማቸው ውስጥ የሚገኘውን የስኳር መጠን እንዴት እየተቆጣጠሩት እንደሆነ የራሳቸው የመርመሪያ 
መሳሪያ(ጉሉኮሜትር) በቤታቸው በሚጠቀሙ እና በማይጠቀሙ መካከል ያለውን ልዩነት እና ተያያዥ ወሳኝ ጉዳዮችን 
በተመለከተ በአይደር አጠቃላይ ስፔሻላይዝድ ሆስፒታል የስኳር ህመም ክትትል በሚያደርጉ ህመምተኞች ከጎንደር 
ዩኒቨርሲቲ እና ከአይደር አጠቃለቀይ ስፔሻላይዝድ ሆስፒታል ፍቃድ አግኝቶ ምርምር ጥናት እየሰራ ነው፡፡ እርስዎ 
የተመረጡት በዚህ ተቋም የስኳር ህመም ክትትል በማድረግ ላይ ስለሚገኙ እና በእድል ወይም በእጣ ነው፡፡ በአጠቃላይ 
እድሜያቸው 18 እና ከዚህ  አመት በላይ የሆኑ ስኳር ህመምተኞች ይሳተፋሉ፡፡ የእርስዎ ተሳትፎ ሙሉ በሙሉ የእርስዎ 
ፍቃደኝነት ላይ የተመሰረተና በጥናቱ መሳተፍ ያለመሳተፍ መብት አሎዎት፡፡ ለመሳተፍ ፈቃደኛ ከሆኑ በኋላም በፈለጉት 
ጊዜ ማቋረጥ ወይም ማቆም ይችላሉ፡፡ በጥናቱ ባለመሳተፍዎ የሚደርስብዎ ጉዳት የለም፡፡ በጥናቱ ለመሳተፍ ከተስማሙ 
ስለራሰዎ የግል ሁኔታ እና ተያያዥ ጉዳዮች እስከ 15 ደቂቃ ሊወስድ የሚችል የተወሰኑ ጥያቄዎች እንጠይቆታለን፡፡  
በመቀጠል የሰለጠነ ነርስ ወይም የላብራቶሪ ባለሞያ ከክንዶ ላይ  ከ3ml-5ml ደም ለስኳር እና የስብ መጠን ለማወቅ 
ለላብራቶሪ ምርመራ ይወሰዳል፡፡ 
በጥናቱ በመሳተፎ ደም በሚቀዳበት ጊዜ ከሚሰማዎ ትንሽ ህመም በስተቀር የሚደርስብዎ ጉዳት የለም፡፡በዚህ ጥናት 
በመሳተፎ በቀጥታ የሚያገኙት ጥቅም(ገንዘብ) ባይኖርም በጥናቱ በሚገኙ ግኝቶች የስኳር ህመም ህክምና ውጤትን 
በተመለከተ በተወሰነ መልኩ ለማሻሻል በመገመት የጥቅሙ ተቛዳሽ ይሆናሉ ብለን እናምናለን፡፡ ከጥናቱ  የስኳር 
ህመምተኞች የስኳር መመርመሪያ መሳሪያ(ጉሉኮሜትር)አጠቃቀም ልምድዎን እንዴት ማሻሻል እንዳለብዎ ይረዳሉ፡፡ 
ከዚህም በተጨማሪ የጥናቱ ውጤት የስኳር ህመምተኞች የግል መመርመሪያ መሳሪያቸውን በመጠቀም በደማቸው ውስጥ 
የሚገኘውን የስኳር መጠን በትክክለኛው መጠን ለመቆጣጠር እና የሚወስዱትን መድሀኒት መጠን ለመመጠን  ልምድ 
ይበልጥ ለማሻሻል ለሌሎች ተመራማሪዎች በዚህ ዙሪያ ለሚሰሩ አካላት እንደመነሻ ያገለግላል፡፡  
ኣላማውን ተረድተውና ጊዜውትን ሰውተው በዚህ ጥናት ለመሳተፍና እውነተኛ መረጃ ለመስጠት ፍቃደኛ በመሆኖው 
በቅድሚያ እናመሰግናለን፡፡ማንኛውም የሚሰጡት መረጃ ለምርምሩ አላማ ብቻ የሚውልና ሚስጥርነቱውም የሚጠበቅ 
መሆኑን ላረጋግጥልዎ እወዳለሁ፡፡ 
በድጋሚ አመሰግናለሁ! 
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Annex 3.2: Amharic version subject informed consent form  
የስምምነት መጠየቂያ/ማረጋገጫ ቅፅ  
ከላይ በሰጠሆዎት መረጃ መሰረት በዚህ ጥናት ለመሳተፍ ፍቃደኛ  ነዎት 1) አዎ (ቃለ መጠይቁን ቀጥሉ )  
2) አይደለሁም  (ምክንያቱን ፅፈህ ወደሚቀጥለዉ ተሳታፊ እለፍ)  
መላሽ/ተሳታፊ   
ፊርማ ______________________ ቀን  __________________  
ጠያቂ  
ስም ____________________________________ ፊርማ ________________  
የመጠይቁ ቁጥር_____________________  
መጠይቁ የተካሄደበት ቀን _________ መጠይቁ የተጀመረበት ሰአት ______የተጠናቀቀበት ሰአት ______  
የቃለ መጠይቁ ዉጤት 1) ሙለ በሙሉ የተሞላ 2)በከፊል የተሞላ 3) ምንም ያልተሞላ  
በተቆጣጣሪዎች ተረጋግጧል ፡፡ስም ________________________ፊርማ _____________  
ለማንኛውም አይነት ጥያቄ እና መረጃ ዋና አጥኚውን ወይም አማካሪዎችን  ማነጋገር ይችላሉ፡ 
 
የዋና ተመራማሪው አድራሻ፤ 
ሰይፉ ሚደቅሳ 
 ኢ-ሜይ ል ፣ seifumid2000@yahoo.com 
ስ ል ክ ፣ +251-911-911692/0914132251 
አማካሪዎች 
ሀብታሙ  ወንድይፍራው (MSc) 
ስልክ ቁጥር፡ 0910818289 
ኢ-ሜይል ፡habtamuw97@gmail.com 
 
ስንታየው አምባቸው (MSc) 
ስልክ ቁጥር፡ 0938279709 
ኢ-ሜይል፡ sinte.ambachew@gmail.com 
ትእዛዝ ፤ተሳታፊዎቹ የሚሰጡትን ማንኛዉንም መልስ ከተሰጡት አማራጮች ዉስጥ ለይተህ አክብብ ወይም በቁጥር 
አስቀምጥ፡፡ 
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Annex 3.3 Questionnaire (Amharic version) 
ክፍል አንድ፡ ማህበራዊ ኢኮኖሚያዊ ሁኔታ እና ከስኳር ህመም ጋር ተያያዥ ጉዳዮች  መጠይቅ 
ተ.ቁ   ጥያቄዎች  አማራጭ መልሶች  
101 እድሜ---------------(በቁጥር ይፃፍ) 
 
 
102 ጾታ 1. ወንድ 
2. ሴት 
103 የትምህርት ደረጃ  
 
   1. መፃፍና ማንበብ የማይችሉ  
   2. መፃፍና ማንበብ የሚችሉ 
   3. አንደኛ ደረጃ (1-8) 
   4. ሁለተኛ ደረጃ(9-12)  
   5. ኮሌጅ/ዩንቨርስቲና ከዚያ በላይ  
104 የስራሁኔታ(ከአንድ በላይ መልስ መስጠት 
ይችላሉ)  
 
     1. ተማሪ  
     2. የመንግስት ስራተኛ  
     3. የግል ስራ  
     4.ነጋዴ 
     5. ስራ የሌለው  
     6. ቤት እመቤት  
     7. ሌላ ካለው ይጠቀስ-------------- 
105 የጋብቻ ሁኔታ 1. ያገባ 
2. ያላገባ 
3. የፈታ/በሞት የተለየ 
106 የቤተሰብ ወርሃዊ ገቢ (በብር) _________ 
(በቁጥር ይፃፍ) 
 
የመኖሪያ ቦታ 1. ከተማ 
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107 2. ገጠር 
108 በቤተሰብ ውስጥ በህክምና የተረጋገጠ የስኳር 
በሽታ ያለበት አለን?  
     1. አዎ  
     2. የለም  
     3. አላውቅም 
109 የስኳር ህመም ዐይነት ያውቁታል? 
ካላወቁት ከካርዳቸው ላይ ይመልከቱ 
 
      1.ዓይነት አንድ 
     2. ዓይነት ሁለት 
     3.አላውቅም 
110 የስኳር ህመምተኛ መሆኖን ካወቁ ምን ያህል 
አመት አድርገዋል?_____________ 
 
111 በደም  ውስጥ ያለውን የስኳር መጠን 
ለመቆጣጠር የሚወስዱት መድሓኒት? 
1. እንሱሊን በመርፌ 
2. በአፍ የሚወሰድ ክኒኒ 
3. ሁለቱንም 
4. በምግብ ብቻ መቆጣጠር 
112 የሰውነት እንቅስቃሴ አዘውትረው ያደርጋሉ? 1. አዎ 
2. አላደርግም 
113 አልኮል ይጠጣሉ? 1. አዎ 
2.አልጠጣም 
114 ሲጋራ ያጨሳሉ? 1. አዎ 
2. አላጨስም 
115 በቤቶ የግሎ የስኳር መመርመሪያ 
መሳሪያ(ጉሉኮሜትር) አሎት? 
1. አለኝ 
2. የለኝም 
116 በዚህ ስድስት ወር ውስጥ ምን ያህል ጊዜ 
የስኳር ህመም ክትትል ለማድረግ ወደዚህ 
ሆስፒታል መተዋል? 
------------------------------ 
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ክፍል ሶስት፡የላብራቶሪ ምርመራ ውጤት     የመለያ ቁጥር---------------------- 
1. ምግብ ሳይበላ  በደም ውስጥ ያለው የስኳር መጠን(FBS)  
FBS ______________________ 
HA1c _____________________ 
3. ምግብ ሳይበላ  በደም ውስጥ ያለው የስብ መጠን Lipid profile 
             Total cholesterol _______________ 
 
              Triglyceride       _______________ 
 
              HDL-C              _______________ 
 
              LDL-C            ________________ 
 
 Dyslipidemia   A. አዎን         B. ኖርማል 
 
III. Anthropometric measurements   code no.___________________________ 
1. የሰውነት ክብደት ጠቛሚ (BMI )  ክብደት(weight) ______________________kg 
                               ቁመት(Hight)_________________________m 
                                      = W/H2 (ክ/ቁ2) 
                                       
_____________________________________________________________Kg/m2               
                     A. ዝቅተኛ                         B. ኖርማል         C. ወፍራም      D. በጣም ወፍራም                                         
 
2. የደም ግፊት መጠን  (Blood pressure )BP _______________mm/hg    
የደም ግፊት መጠን  (Hypertensive )  A. አለው         B. ኖርማል 
መረጃውን የሰበሰበው ስም__________________________ ቀን----------------------------- ፊርማ----- 
የተቆጣጣሪው  ስም----------------------------------- ቀን ---------------------------- ፊርማ--------------- 
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ወርቃማ ጊዜውን ሰውተው ለጥናቱ ስለተባበሩን ከልብ እናመሰግናለን! 
Annex 4: Tigrigna version participants information sheet, consent and questionnaire 
form 
ናይ ተሓተትቲ/ መለስቲ ሓበሬታ ቅጥዒከመይሓዲርኩም / ውዒልኩም፡፡ሽመይ ------------------------------- 
ይበሃል:: ናብዚ ዝመፃእኩ ናይ ጎንደር ዩኒቨርሲቲ ሕክምናን ጥዕና ሳይንስን ኮሌጅ፤ ባዮሜዲካልን ላቦራቶሪ ሳይንስ ት/ቤት፤ 
ክሊንካል ኬሚስትሪ ት/ክፍሊ ናይ ካልኣይ ዲግሪ ተማሃሪ ዝኮነ ሰይፉ ሚደቅሳ ወኪለእየ፡፡ ካልኣይ ዲግሪ ንክምረቅ ናይ 
ሽኮር  ሕሙማት አብደሞ ምውሽጢ ዝርከብ ናይ ሽኮር መጠን ከመይ እንዳተቆፃፀርዎከም ዝሆነ ናይ ባዕሎም መመርመሪ 
መሳሪሒ(ጉሉኮሜትር)አብ ገዝኦም ዝጥቀሙን ዘይጥቀሙን ሞንጎ ዘሎ አፈላላይን ተተሓሓዝቲ ወሰንቲ ጉዳያትን 
ብዝምልከት ኣብ ዓይደር አጠቃላይ ስፔሻላይዝድ ሆስፒታል ናይ ሽኮር ሕማም ክትትል ዝገብሩ ሕሙማት ካብ ጎንደር 
ዩኒቨርሲቲ ን አጠቃላይ  ስፔሻላይዝድ ሆስፒታል ንፍቃድ ረኪቡ ምርምር እናሰርሐ አዩ፡፡ 
ንሶም/ንሰ ንዝተመረፅሉ/ፃሉኣ ብዚ ትካል ናይ ሕማም ሽኮር ክትትል ኣብምግባር ስለዝረከቡን ብዕድል ወይከዓ ብዕፃ እዩ፡፡ 
ብሓፈሻ ዕድሚኦም 18ን ካብኡ ንላዕሊን ዝኮኑ ናይሽኮር ሕሙማት ይሳተፉ እዮም፡፡ ናቶም ተሳትፎ ሙለእ ብሙሉእ 
ብናቶም ፍâደኝነት ዝተመስረተ ኮይኑ አብዚ ፅንዓት ናይምስታፍ ንዘይምስታፍን መሰል አለዎም ንምስታፍ ፍâደኛ 
ድሕሪምእዉን አብዝደለይዎ ግዜ ምቁራፅ ይክእሉ፡፡ ኣብዚ ፅንዓት ብዘይምስታፍኩም ዝበፅሐኩም ጉድኣት የለን፡፡ኣብዚ 
ፅንዓት ንምስታፍ ተተስማዕሚዕም ብዛዕባኩም ዉልቀ ጉዳይን ናይሽኮር ህማም ንተተሓሓዝቲ ጉዳያት ዝምልከት  ክሳብ 
15 ደቂቃ ክወስዱ  ዝእሉ ዝተወሰኑ ሕቶታት ክንሓቶምኢና፡፡ ካብኡ ብምቕፃል ብዝሰልጠነ ነርስ ወይ ላብራቶሪ ባዓልሞያ 
ካብኢዶም 5 ሚሊሊትር ደም ንሽኮርን ናይ ስብሒ መጠንን ንላብራቶሪ ምርመራ ክቕድሑእዮም፡፡ 
ኣብዚ ፅንዓት ብምስታፍኩም ደም ኣብዝውሰደሉ ጊዜ ካብ ዝስመዖም ንእሽተይ ሕማም ወፃኢ ዝበፅሖም ጉድኣት የለን፡፡ 
ኣብዚ ፅንዓት ብምስታፍኩም ብቐጥታ ዝረክቡዎ ጥቕሚ (ገንዘብ) የለን ኮይኑ ግና በዚ ፅንዓት ኣቢሎም ዝርከቡ ዉፅኢት 
ናይ ሕማም ሽኮር ሕክምና ውፅኢት ብዝምልከት ብዝተወሰነ መልክዑ ንምምሕያሽ ብምግማት ናይዚ ጥቕሚ ተቃደስቲ 
ክትእዮኑም ኢልና ንኣምን፡፡ ካብዚ ፅንዓት ናይ ሽኮር ሕሙማት ናይ ሽኮር መመርመሪ መሳሪሒ(ጉሉኮሜትር) አጠቃቀማ 
ልምዶም ከመይ ከመሓይሹከም ዘለዎም ይፈልጡ ካብዚ ብተወሳኪ ናይዚ ፅንዓት ውፅኢት ናይ ሽኮር ሕሙማት ናይ 
ባዕሎም መመርመሪ  መሳርሒ ብምጥቃም አብደሞም ውሽጢ ዝርከብ ናይ ሽኮር መጠንን ምቁፅፃርን ዝወስድዎ መድሓኒት 
መጠን ንምምጣን ዝበለፀ ልምዲ ንምምሕያሽንን ካልኦት አብዚ ዙርያ ዝሰርሑ ተመራመረቲ አካላት ከምመበገሲ 
የገልግል፡፡ 
ናይዚ ፅንዓት ዓላማ ተረዲኦም ጊዜኦም ሰዊኦም አብዚ ፅንዓት ንምስታፍ ንሓቀኛ ሓበሬታ ንምሃብ ፍቃደኛ ስለዝኮኑ 
ብቅድሚያ ብጣዕሚ የመስግን፡፡ ኩሉ ዝህበዎ ሓበሬታ ነዚ ፅንዓት ዓላማ ጥራሕ ከምዝውዕል ንሚስጥሩ ዝተሓለወ ምሆኑን 
ከረጋግፀልኩም ይፎቱ፡፡ 
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ብድጋሚ የቀንየለይ!! 
Annex 4. 2 : Tigrigna version subject informed consent form  
ናይ ስምምዕነት መሕተቲ/መረጋገፂ ቅጥዒ 
ኣብ ላዕሊ ብዝሃብክዎም መረጃ መሰረት ኣብዚ ፅንዓት ንምስታፍ ፍቃደኛ ድዮም? 
1) እወ (እቲ ቃለ መሕትት ቀፅል ) 
2) አይኮንኩን (ምክንያቱ ፅሒፍካ ናብ ዝቕፅል ተሳታፋይ ሕለፍ)  
ናይ ተሳታፊ 
ፌርማ  ______________________                ዕለት__________________  
ናይሓታቲ 
ሽም ____________________________________     ፌርማ ________________  
ናይዚ መሕትት ቁፅሪ_____________________  
ቃለ መሕትት ዝተካየደሉ ዕለት ______________   ቃለ መሕትት ዝተጀመረሉ ሰዓት ______   ዝተጠናቐቐሉ ሰዓት  
______ 
ናይ ቃለ መሕትት ውፅኢት  1) ሙሉእ ብሙሉእ ዝተመልአ  2)ብከፊል ዝተመልአ  3) ምንም ዘይተመልአ 
ብተቆፃፀርቲ ተረጋጊፁ እዩ፡፡ ሽም ________________________   ፌርማ _____________  
 
ንዝኮነ ዓይነት ሕቶን ሓበሬታን ዋና ተመራማሪ ምዝርራብ ይከኣል እዩ፡፡ 
ናይ ዋና ተመራማሪ አድራሻ 
ሰይፉ ሚደቅሳ 
ኢ-ሜይል፣ seifumid2000@yahoo.com 
ስልኪ፣+251-911-911692 
አማካሀሪቲ 
ሀብታሙ  ወንድይፍራው (MSc) 
ስልክ ቁጥር፡ 0910818289 
ኢ-ሜይል ፡habtamuw97@gmail.com 
 
ስንታየው አምባቸው (MSc) 
ስልክ ቁጥር፡ 0938279709 
ኢ-ሜይል፡ sinte.ambachew@gmail.com 
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ትእዛዝ፤  ተሳተፍቲ ዝህብዎ መልሲ ካብቶም ዝቐረቡ መማረፂ ዉሽጢ ፈሊካ አክብብ ወይ ብቁፅሪ ኣቐምጥ 
 
 
 
Annex 5.3 Questionnaire (Tigrigna version) 
ክፍሊሓደ፡ ማሕበረሰባዊን ኢኮኖሚያዊን ኩነታትን ምስ ሕማም ሽኮር ተተሓሓዘቲ ጉዳያት ቃለ መሕትት 
ተ.ቁ  ሕቶታት መማረፂመልስታት ኮ
ድ 
101 ዕድመ---------------(ብቁፅሪይፅሓፉ)   
102 ፆታ 1. ተባዕታይ 0 
2. አንስተይቲ 1 
103 ደረጃ ትምህርቲ 
 
1. .ምንባብን ምፅሓፍን ዘይክእል 0 
2. .ምንባብን ምፅሓፍን ዝክእል 1 
   3. .ቀዳማይ ብርኪ(1-8) 2 
   4. ካልኣይ ብርኪ(9-12) 3 
   5. ኮሌጅ/ዩንቨርስቲን ልዕሊኡን 4 
104 ኩነታት ስራሕ (ካብ ሐደን ላዕሊ መልሲ ምሃብ 
ይክእሉ)  
 
1. ተምሃራይ /ተምሃሪት 0 
2. ናይ መንግስቲ ሰራሕተኛ 1 
3. ናይ ግሊ ስራሕ 2 
4. ነጋዳይ 3 
5. ስራሕ ዘይብሉ 4 
6.በዓልቲ ሓዳር 5 
      7. ካሊእ ተሃልዩ ይጠቐስ_____________ 6 
105 ኩነታት ሓዳር 1. ዝተመርዐወ/ዝተመርዐወት 0 
2. ዘይተመርዐወ/ዘይተመርዐወት 1 
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3. ዝተፋተሐ/ዝተፋተሐትወይሰብኣያዝሞታ/ሰበይቱዝ
ሞተቶ 
2 
106 ናይ ስድራ ወርሓዊ አታዊ (ብቅርሺ) _________ 
(ብቁፅሪ ፀሓፍ) 
  
107 መንበሪ ቦታ 3. ከተማ 0 
4. ገጠር 1 
108 ኣብ ቤተሰብኩም ብሕክምና ዝተረጋገፀ ሕማም 
ሽኮር ዘለዎ ኣሎዶ ?  
     1.  እወ 0 
     2. የለን     1 
109 ናይ ሽኮር ዓይነቶም ይፈልጡ ዶ? ተዘይፈሊጦሞ 
ካብ ካርዶም ይርኣዩ 
 
1. ዓይነት ሓደ 0 
2. ዓይነት ክልተ 1 
3. ኣይፈልጥን 2 
110 ሕማም ሽኮር ከምዘለዎም ካብ ዝፈልጡ ክንደይ 
ዓመት ገይሮም?_____________ 
  
111 ኣብደሞም ውሽጢ ንዘሎ ናይሽኮር መጠን 
ንምቁፅፃር  መድሓኒት? 
5. እንሱሊንብመርፍእ 0 
6. ብአፍዝውሰድከኒና 1 
7. ክልቲኡ 2 
8. ብምግቢ ጥራሕ 3 
112 ናይ ሰውነት ምንቅስቃስ አዘውቲሮም ይገብሩ ዶ? 3. እወ 0 
4. ኣይገብርን 1 
113 አልኮል ይሰትዩ ዶ? 2. እወ 0 
3. ኣይሰትን 
 
1 
114 ሽጋራ ተትክህ ዲኩም? 3. እወ 0 
4. አየትክን 1 
115 3. እወ 0 
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ኣብ ገዝኦም ናይ ውልቆም ናይ ሽኮር መመርመሪ 
መሳርሒ(ጉሉኮሜትር) ኣለዎም ዶ? 
 
4. የብለይን 1 
116 ኣብዚህ 6 ወህሪ ውሽጢ ክንዳ ጊዜ ናይ ሽኮር ህማም 
ክትትል ንምግባር አብዚህ ሆስፒታል መጺሁም?    
________________ 
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